To: John Howard, MD, MPH, JD, LLM, MBA, NIOSH Docket Office
"We support the intent behind NIOSH’s Hazardous Drug List of keeping workers safe from unnecessary harm, but do not believe that available evidence points to a need for the inclusion of liraglutide. Therefore, we respectfully ask that you remove the drug from the list. "
Read the Full Summary 
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.